AKT1 and acute lymphoblastic leukemia: Overall, these findings demonstrated that the combination of nelarabine with ZSTK-474 has a potent cytotoxic activity also in primary cells from relapsed T-ALL patients with upregulated PI3K/AKT signaling and resistant to nelarabine in vitro.